ABSTRACT
Introduction
Blood transfusion therapy has evolved remarkably over the years since its introduction into clinical practice. It has also become an indispensable life saving measure in patient care. The use of blood and blood components in clinical practice has, nonetheless, continued to face challenges demanding sustained efforts aimed at improvement in its use. [1] Prominent among such challenges is the issue of transfusion transmitted diseases as well as the unavailability of a reliable safe donor pool particularly in developing nations. The goal of modern transfusion therapy is to provide appropriate replacement therapy with blood components (red cells, platelets, fresh frozen plasma, cryo-precipitate etc.) as opposed to the whole blood for patients with specific haematological deficiencies. [2] Blood has been a scarce 'commodity' ever since, and because of that, many lives are lost which could have been saved. The main reason is that no artificial alternative is available till date. The only logical solution to this dilemma, at present, appears to use one unit of blood for more than one patient -Component Therapy. It is just like using a specific drug for a specific malady instead of a combination -in fact "Tailor Made" use of blood. This concept came to Madhya Pradesh in 2002 and gained momentum in 2003.
Materials and Methods
In the state of the art blood bank of M.Y. Hospital, Indore (MYH), components are being supplied to the patients as per their specific need. The data has been retrieved from the records of the blood bank.
Results
A total of 100,071 transfusion episodes were reviewed and analysed. The distribution of collection of blood year wise ( The present study may be a preliminary indicator that there may be a better awareness and appreciation of component transfusion by clinicians over the period. Unfortunately, the increased awareness of clinicians of the need to use component transfusion as against whole blood transfusion has not been met by a corresponding enhanced capacity of our blood banks towards the provision of blood components for clinical use.
The provision of a regular supply of safe blood components to hospital. In contemporary transfusion practice, there is little justification for whole blood transfusion. An area of current debate in the area of transfusion for trauma patients relates to the management of trauma patients with massive bleeding.
In developed transfusion centers where component therapy is the rule, it has been proposed that coagulopathic trauma patients be primarily resuscitated with FFP in a ratio of 1:1:1 to red blood cells and platelets, virtually receiving "reconstituted whole blood." Thus transfusion of fresh whole blood is justified in such circumstances. However none of the whole blood transfusions given peri-operatively in this audit could be justified and were thus adjudged inappropriate.
Red cell transfusion is the least inappropriately used blood component in this study, however the situation can still be improved upon. Anaemia (reduction in haematocrit for the age and sex in a patient) is described as mild if the packed cell value is greater than or equal to (>) 30% and physicians should be discouraged from routinely transfusing patients with mild anaemia.
The "optimal" haemoglobin concentration for pre and post-operative patients depends on the patient and the belief that a haemoglobin value <10 g/dl (haematocrit <30%) indicates a need for red cell transfusion has been challenged. [3] [4] [5] This is because cardiac output does not change significantly until the Hb decreases <7g/dl.
Tissue oxygenation is generally maintained at haematocrit levels as low as 30% as long as the blood volume remains normal. [6] [7] [8] Between the limits of haematocrit levels 18%-30%, (moderate anaemia), the decision to transfuse should be based on a consideration of the patient's age, cardiovascular and respiratory status, activity level, symptoms, underlying diagnosis and the state of the bone marrow activity. Many anaemic patients at or above haematocrit of 25% (Hb 8g/dl) do not need transfusion. However, the physiologic adjustments to chronic anaemia have a limit and particularly in the elderly patients with myocardial or vascular disease.
Conclusion
The data reveals that packed cells occupy the first place with FFP being a close second, with platelet concentrate, PRP and cryoprecipitate lagging far behind. A spurt in the use of PRP was seen in the year 2006 which can be attributed to the outbreak of Dengue and Chicken Guniya with their resultant side effects of thrombocytopenia. This slow growth is most probably due to lack of awareness amongst clinicians and needs urgent corrective measures in the form of awareness campaigns for increasing the rational use of blood components. We can add our recommendation to that of WHO stating that while encouraging the use of appropriate blood components care should be taken that irrational use is avoided to prevent unnecessary transfusions.
